Skip to main content
Erschienen in: Endocrine 1/2023

11.05.2023 | Original Article

MicroRNA-130a-3p impedes the progression of papillary thyroid carcinoma through downregulation of KPNB1 by targeting PSME3

verfasst von: Yan Wang, Jinmei Xu, Xiaodan Zhu, Hongyu Kuang

Erschienen in: Endocrine | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Background:

Papillary thyroid carcinoma (PTC) is the main type of thyroid cancer (THCA). Despite the good prognosis, some PTC patients may deteriorate into more aggressive disease, leading to poor survival. Our study aimed to explore the role of microRNA (miR)-130a-3p in regulating PTC.

Methods:

After transfection with miR-130a-3p-mimic, OE-PSME3, or miR-130a-3p-mimic + OE-KPNB1 in PTC cells (TPC-1), CCK-8, Transwell, scratch, and flow cytometry experiments were performed to analyze TPC-1 cell proliferation, invasion, migration, and apoptosis. Western blotting was used to detect proliferation or invasion-related protein markers (PCNA, E-cadherin, and N-cadherin). The RNA22 database, dual-luciferase reporter assay, and RNA pull-down assay were applied for the prediction and verification of the binding site between miR-130a-3p and PSME3. Pan-cancer software identified a positive correlation between PSME3 and KPNB1 in THCA. Co-immunoprecipitation was utilized to verify the interaction of PSME3 with KPNB1. Nude mice were transplanted with TPC-1 cells overexpressing miR-130a-3p. The tumors were isolated for detection of the expression of miR-130a-3p, PSME3, KPNB1, Ki-67, and CD31.

Results:

miR-130a-3p was lowly expressed in PTC cell lines. Upregulation of miR-130a-3p repressed the expression of PSME3 and KPNB1 and reduced the malignancy of TPC-1 cells in vitro, shown by inhibited cell proliferation, invasion, migration, and the expression of PCNA and N-cadherin. Also, overexpressed miR-130a-3p inhibited the growth of xenograft tumors in nude mice. miR-130a-3p bound to PSME3 which interacted with KPNB1.

Conclusion:

miR-130a-3p impedes the progression of PTC by downregulating PSME3/KPNB1.
Literatur
1.
Zurück zum Zitat F. Khatami, S.M. Tavangar, Liquid biopsy in thyroid cancer: new insight. Int. J. Hematol. Oncol. Stem Cell. Res. 12(3), 235–248 (2018)PubMedPubMedCentral F. Khatami, S.M. Tavangar, Liquid biopsy in thyroid cancer: new insight. Int. J. Hematol. Oncol. Stem Cell. Res. 12(3), 235–248 (2018)PubMedPubMedCentral
2.
Zurück zum Zitat Z.W. Baloch, V.A. LiVolsi, Special types of thyroid carcinoma. Histopathology 72(1), 40–52 (2018)PubMedCrossRef Z.W. Baloch, V.A. LiVolsi, Special types of thyroid carcinoma. Histopathology 72(1), 40–52 (2018)PubMedCrossRef
3.
Zurück zum Zitat J. Mao, Q. Zhang, H. Zhang, K. Zheng, R. Wang, G. Wang, Risk factors for lymph node metastasis in papillary thyroid carcinoma: a systematic review and meta-analysis. Front Endocrinol. (Lausanne) 11, 265 (2020)PubMedCrossRef J. Mao, Q. Zhang, H. Zhang, K. Zheng, R. Wang, G. Wang, Risk factors for lymph node metastasis in papillary thyroid carcinoma: a systematic review and meta-analysis. Front Endocrinol. (Lausanne) 11, 265 (2020)PubMedCrossRef
4.
Zurück zum Zitat A. Prete, P. Borges de Souza, S. Censi, M. Muzza, N. Nucci, M. Sponziello, Update on fundamental mechanisms of thyroid cancer. Front Endocrinol. (Lausanne) 11, 102 (2020)PubMedCrossRef A. Prete, P. Borges de Souza, S. Censi, M. Muzza, N. Nucci, M. Sponziello, Update on fundamental mechanisms of thyroid cancer. Front Endocrinol. (Lausanne) 11, 102 (2020)PubMedCrossRef
5.
Zurück zum Zitat M. Correia de Sousa, M. Gjorgjieva, D. Dolicka, C. Sobolewski, M. Foti, Deciphering miRNAs’ Action through miRNA Editing. Int. J. Mol. Sci. 20(24), (2019). M. Correia de Sousa, M. Gjorgjieva, D. Dolicka, C. Sobolewski, M. Foti, Deciphering miRNAs’ Action through miRNA Editing. Int. J. Mol. Sci. 20(24), (2019).
6.
Zurück zum Zitat R. Rupaimoole, F.J. Slack, MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat. Rev. Drug Discov. 16(3), 203–222 (2017)PubMedCrossRef R. Rupaimoole, F.J. Slack, MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat. Rev. Drug Discov. 16(3), 203–222 (2017)PubMedCrossRef
7.
Zurück zum Zitat Y.T. Fu, H.B. Zheng, D.Q. Zhang, L. Zhou, H. Sun, MicroRNA-1266 suppresses papillary thyroid carcinoma cell metastasis and growth via targeting FGFR2. Eur. Rev. Med. Pharmacol. Sci. 22(11), 3430–3438 (2018)PubMed Y.T. Fu, H.B. Zheng, D.Q. Zhang, L. Zhou, H. Sun, MicroRNA-1266 suppresses papillary thyroid carcinoma cell metastasis and growth via targeting FGFR2. Eur. Rev. Med. Pharmacol. Sci. 22(11), 3430–3438 (2018)PubMed
8.
Zurück zum Zitat F. Liu, K. Lou, X. Zhao, J. Zhang, W. Chen, Y. Qian, Y. Zhao, Y. Zhu, Y. Zhang, miR-214 regulates papillary thyroid carcinoma cell proliferation and metastasis by targeting PSMD10. Int. J. Mol. Med. 42(6), 3027–3036 (2018)PubMedPubMedCentral F. Liu, K. Lou, X. Zhao, J. Zhang, W. Chen, Y. Qian, Y. Zhao, Y. Zhu, Y. Zhang, miR-214 regulates papillary thyroid carcinoma cell proliferation and metastasis by targeting PSMD10. Int. J. Mol. Med. 42(6), 3027–3036 (2018)PubMedPubMedCentral
9.
Zurück zum Zitat W.J. Wang, Y. Yuan, D. Zhang, P. Liu, F. Liu, miR-671-5p repressed progression of papillary thyroid carcinoma via TRIM14. Kaohsiung J. Med. Sci. 37(11), 983–990 (2021)PubMedCrossRef W.J. Wang, Y. Yuan, D. Zhang, P. Liu, F. Liu, miR-671-5p repressed progression of papillary thyroid carcinoma via TRIM14. Kaohsiung J. Med. Sci. 37(11), 983–990 (2021)PubMedCrossRef
10.
Zurück zum Zitat X. Wen, J. Du, X. Wang, Circ_0039411 promotes papillary thyroid carcinoma development through mediating the miR-423-5p/SOX4 signaling. Int. J. Biol. Markers 36(4), 10–20 (2021)PubMedCrossRef X. Wen, J. Du, X. Wang, Circ_0039411 promotes papillary thyroid carcinoma development through mediating the miR-423-5p/SOX4 signaling. Int. J. Biol. Markers 36(4), 10–20 (2021)PubMedCrossRef
11.
Zurück zum Zitat W. Hu, X. Zheng, J. Liu, M. Zhang, Y. Liang, M. Song, MicroRNA MiR-130a-3p promotes gastric cancer by targeting Glucosaminyl N-acetyl transferase 4 (GCNT4) to regulate the TGF-beta1/SMAD3 pathway. Bioengineered 12(2), 11634–11647 (2021)PubMedPubMedCentralCrossRef W. Hu, X. Zheng, J. Liu, M. Zhang, Y. Liang, M. Song, MicroRNA MiR-130a-3p promotes gastric cancer by targeting Glucosaminyl N-acetyl transferase 4 (GCNT4) to regulate the TGF-beta1/SMAD3 pathway. Bioengineered 12(2), 11634–11647 (2021)PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat L. Liu, P. Wang, Y.S. Wang, Y.N. Zhang, C. Li, Z.Y. Yang, Z.H. Liu, T.Z. Zhan, J. Xu, C.M. Xia, MiR-130a-3p alleviates liver fibrosis by suppressing hscs activation and skewing macrophage to Ly6C(lo) phenotype. Front Immunol. 12, 696069 (2021)PubMedPubMedCentralCrossRef L. Liu, P. Wang, Y.S. Wang, Y.N. Zhang, C. Li, Z.Y. Yang, Z.H. Liu, T.Z. Zhan, J. Xu, C.M. Xia, MiR-130a-3p alleviates liver fibrosis by suppressing hscs activation and skewing macrophage to Ly6C(lo) phenotype. Front Immunol. 12, 696069 (2021)PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat X. Luo, J. Wang, X. Wei, S. Wang, A. Wang, Knockdown of lncRNA MFI2-AS1 inhibits lipopolysaccharide-induced osteoarthritis progression by miR-130a-3p/TCF4. Life Sci. 240, 117019 (2020)PubMedCrossRef X. Luo, J. Wang, X. Wei, S. Wang, A. Wang, Knockdown of lncRNA MFI2-AS1 inhibits lipopolysaccharide-induced osteoarthritis progression by miR-130a-3p/TCF4. Life Sci. 240, 117019 (2020)PubMedCrossRef
14.
Zurück zum Zitat G.L. Song, M. Xiao, X.Y. Wan, J. Deng, J.D. Ling, Y.G. Tian, M. Li, J. Yin, R.Y. Zheng, Y. Tang, G.Y. Liu, MiR-130a-3p suppresses colorectal cancer growth by targeting Wnt Family Member 1 (WNT1). Bioengineered 12(1), 8407–8418 (2021)PubMedPubMedCentralCrossRef G.L. Song, M. Xiao, X.Y. Wan, J. Deng, J.D. Ling, Y.G. Tian, M. Li, J. Yin, R.Y. Zheng, Y. Tang, G.Y. Liu, MiR-130a-3p suppresses colorectal cancer growth by targeting Wnt Family Member 1 (WNT1). Bioengineered 12(1), 8407–8418 (2021)PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Y. Wang, M. Shi, Z. Hong, J. Kang, H. Pan, C. Yan, MiR-130a-3p has protective effects in alzheimer’s disease via targeting DAPK1. Am. J. Alzheimers Dis. Other Demen 36, 15333175211020572 (2021)PubMedCrossRef Y. Wang, M. Shi, Z. Hong, J. Kang, H. Pan, C. Yan, MiR-130a-3p has protective effects in alzheimer’s disease via targeting DAPK1. Am. J. Alzheimers Dis. Other Demen 36, 15333175211020572 (2021)PubMedCrossRef
16.
Zurück zum Zitat J. Zhao, H. Wang, J. Zhou, J. Qian, H. Yang, Y. Zhou, H. Ding, Y. Gong, X. Qi, Y. Jiao, P. Ying, L. Tang, Y. Sun, W. Zhu, miR-130a-3p, a preclinical therapeutic target for Crohn’s disease. J. Crohns Colitis 15(4), 647–664 (2021)PubMedCrossRef J. Zhao, H. Wang, J. Zhou, J. Qian, H. Yang, Y. Zhou, H. Ding, Y. Gong, X. Qi, Y. Jiao, P. Ying, L. Tang, Y. Sun, W. Zhu, miR-130a-3p, a preclinical therapeutic target for Crohn’s disease. J. Crohns Colitis 15(4), 647–664 (2021)PubMedCrossRef
17.
Zurück zum Zitat G. Yin, W. Kong, S. Zheng, Y. Shan, J. Zhang, R. Ying, H. Wu, Exosomal miR-130a-3p promotes the progression of differentiated thyroid cancer by targeting insulin-like growth factor 1. Oncol. Lett. 21(4), 283 (2021)PubMedPubMedCentralCrossRef G. Yin, W. Kong, S. Zheng, Y. Shan, J. Zhang, R. Ying, H. Wu, Exosomal miR-130a-3p promotes the progression of differentiated thyroid cancer by targeting insulin-like growth factor 1. Oncol. Lett. 21(4), 283 (2021)PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat D. Fesquet, D. Lleres, C. Grimaud, C. Vigano, F. Mechali, S. Boulon, O. Coux, C. Bonne-Andrea, V. Baldin, The 20S proteasome activator PA28gamma controls the compaction of chromatin. J. Cell Sci. 134(3), (2021). D. Fesquet, D. Lleres, C. Grimaud, C. Vigano, F. Mechali, S. Boulon, O. Coux, C. Bonne-Andrea, V. Baldin, The 20S proteasome activator PA28gamma controls the compaction of chromatin. J. Cell Sci. 134(3), (2021).
19.
Zurück zum Zitat C. Jiao, L. Li, P. Zhang, L. Zhang, K. Li, R. Fang, L. Yuan, K. Shi, L. Pan, Q. Guo, X. Gao, G. Chen, S. Xu, Q. Wang, D. Zuo, W. Wu, S. Qiao, X. Wang, R. Moses, J. Xiao, L. Li, Y. Dang, X. Li, REGgamma ablation impedes dedifferentiation of anaplastic thyroid carcinoma and accentuates radio-therapeutic response by regulating the Smad7-TGF-beta pathway. Cell Death Differ. 27(2), 497–508 (2020)PubMedCrossRef C. Jiao, L. Li, P. Zhang, L. Zhang, K. Li, R. Fang, L. Yuan, K. Shi, L. Pan, Q. Guo, X. Gao, G. Chen, S. Xu, Q. Wang, D. Zuo, W. Wu, S. Qiao, X. Wang, R. Moses, J. Xiao, L. Li, Y. Dang, X. Li, REGgamma ablation impedes dedifferentiation of anaplastic thyroid carcinoma and accentuates radio-therapeutic response by regulating the Smad7-TGF-beta pathway. Cell Death Differ. 27(2), 497–508 (2020)PubMedCrossRef
20.
Zurück zum Zitat M.Z. Bhatti, L. Pan, T. Wang, P. Shi, L. Li, REGgamma potentiates TGF-beta/Smad signal dependent epithelial-mesenchymal transition in thyroid cancer cells. Cell Signal 64, 109412 (2019)PubMedCrossRef M.Z. Bhatti, L. Pan, T. Wang, P. Shi, L. Li, REGgamma potentiates TGF-beta/Smad signal dependent epithelial-mesenchymal transition in thyroid cancer cells. Cell Signal 64, 109412 (2019)PubMedCrossRef
21.
Zurück zum Zitat T. Okamura, S. Taniguchi, T. Ohkura, A. Yoshida, H. Shimizu, M. Sakai, H. Maeta, H. Fukui, Y. Ueta, I. Hisatome, C. Shigemasa, Abnormally high expression of proteasome activator-gamma in thyroid neoplasm. J. Clin. Endocrinol. Metab. 88(3), 1374–1383 (2003)PubMedCrossRef T. Okamura, S. Taniguchi, T. Ohkura, A. Yoshida, H. Shimizu, M. Sakai, H. Maeta, H. Fukui, Y. Ueta, I. Hisatome, C. Shigemasa, Abnormally high expression of proteasome activator-gamma in thyroid neoplasm. J. Clin. Endocrinol. Metab. 88(3), 1374–1383 (2003)PubMedCrossRef
22.
Zurück zum Zitat J. Guo, J. Hao, H. Jiang, J. Jin, H. Wu, Z. Jin, Z. Li, Proteasome activator subunit 3 promotes pancreatic cancer growth via c-Myc-glycolysis signaling axis. Cancer Lett 38, 6161–6167 (2017) J. Guo, J. Hao, H. Jiang, J. Jin, H. Wu, Z. Jin, Z. Li, Proteasome activator subunit 3 promotes pancreatic cancer growth via c-Myc-glycolysis signaling axis. Cancer Lett 38, 6161–6167 (2017)
23.
Zurück zum Zitat M. Jiang, Y. Zhu, H. Yu, Ginsenoside 20(S)-Rg3 suppresses cell viability in esophageal squamous cell carcinoma via modulating miR-324-5p-targeted PSME3. Hum. Exp. Toxicol. 40(11), 1974–1984 (2021)PubMedCrossRef M. Jiang, Y. Zhu, H. Yu, Ginsenoside 20(S)-Rg3 suppresses cell viability in esophageal squamous cell carcinoma via modulating miR-324-5p-targeted PSME3. Hum. Exp. Toxicol. 40(11), 1974–1984 (2021)PubMedCrossRef
24.
Zurück zum Zitat C. Liu, J. Yang, H. Wu, J. Li, Downregulated miR-585-3p promotes cell growth and proliferation in colon cancer by upregulating PSME3. Onco. Targets Ther. 12, 6525–6534 (2019)PubMedPubMedCentralCrossRef C. Liu, J. Yang, H. Wu, J. Li, Downregulated miR-585-3p promotes cell growth and proliferation in colon cancer by upregulating PSME3. Onco. Targets Ther. 12, 6525–6534 (2019)PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat L. Qi, W. He, REGgamma is associated with lymph node metastasis and T-stage in papillary thyroid carcinoma. Med. Sci. Monit 24, 1373–1378 (2018)PubMedPubMedCentralCrossRef L. Qi, W. He, REGgamma is associated with lymph node metastasis and T-stage in papillary thyroid carcinoma. Med. Sci. Monit 24, 1373–1378 (2018)PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat L.E. Kapinos, B. Huang, C. Rencurel, R.Y.H. Lim, Karyopherins regulate nuclear pore complex barrier and transport function. J. Cell Biol. 216(11), 3609–3624 (2017)PubMedPubMedCentralCrossRef L.E. Kapinos, B. Huang, C. Rencurel, R.Y.H. Lim, Karyopherins regulate nuclear pore complex barrier and transport function. J. Cell Biol. 216(11), 3609–3624 (2017)PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Y. Quan, Z.L. Ji, X. Wang, A.M. Tartakoff, T. Tao, Evolutionary and transcriptional analysis of karyopherin beta superfamily proteins. Mol. Cell Proteom. 7(7), 1254–1269 (2008)CrossRef Y. Quan, Z.L. Ji, X. Wang, A.M. Tartakoff, T. Tao, Evolutionary and transcriptional analysis of karyopherin beta superfamily proteins. Mol. Cell Proteom. 7(7), 1254–1269 (2008)CrossRef
28.
Zurück zum Zitat W. Du, J. Zhu, Y. Zeng, T. Liu, Y. Zhang, T. Cai, Y. Fu, W. Zhang, R. Zhang, Z. Liu, J.A. Huang, KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway. Cell Death Differ 28(4), 1284–1300 (2021)PubMedCrossRef W. Du, J. Zhu, Y. Zeng, T. Liu, Y. Zhang, T. Cai, Y. Fu, W. Zhang, R. Zhang, Z. Liu, J.A. Huang, KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway. Cell Death Differ 28(4), 1284–1300 (2021)PubMedCrossRef
29.
Zurück zum Zitat M. Kodama, T. Kodama, J.Y. Newberg, H. Katayama, M. Kobayashi, S.M. Hanash, K. Yoshihara, Z. Wei, J.C. Tien, R. Rangel, K. Hashimoto, S. Mabuchi, K. Sawada, T. Kimura, N.G. Copeland, N.A. Jenkins, In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer. Proc. Natl. Acad. Sci. USA. 114(35), E7301–E7310 (2017)PubMedPubMedCentralCrossRef M. Kodama, T. Kodama, J.Y. Newberg, H. Katayama, M. Kobayashi, S.M. Hanash, K. Yoshihara, Z. Wei, J.C. Tien, R. Rangel, K. Hashimoto, S. Mabuchi, K. Sawada, T. Kimura, N.G. Copeland, N.A. Jenkins, In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer. Proc. Natl. Acad. Sci. USA. 114(35), E7301–E7310 (2017)PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat J. Yang, Y. Guo, C. Lu, R. Zhang, Y. Wang, L. Luo, Y. Zhang, C.H. Chu, K.J. Wang, S. Obbad, W. Yan, X. Li, Inhibition of Karyopherin beta 1 suppresses prostate cancer growth. Oncogene 38(24), 4700–4714 (2019)PubMedPubMedCentralCrossRef J. Yang, Y. Guo, C. Lu, R. Zhang, Y. Wang, L. Luo, Y. Zhang, C.H. Chu, K.J. Wang, S. Obbad, W. Yan, X. Li, Inhibition of Karyopherin beta 1 suppresses prostate cancer growth. Oncogene 38(24), 4700–4714 (2019)PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Z.C. Zhu, J.W. Liu, K. Li, J. Zheng, Z.Q. Xiong, KPNB1 inhibition disrupts proteostasis and triggers unfolded protein response-mediated apoptosis in glioblastoma cells. Oncogene 37(22), 2936–2952 (2018)PubMedPubMedCentralCrossRef Z.C. Zhu, J.W. Liu, K. Li, J. Zheng, Z.Q. Xiong, KPNB1 inhibition disrupts proteostasis and triggers unfolded protein response-mediated apoptosis in glioblastoma cells. Oncogene 37(22), 2936–2952 (2018)PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat M. Jurikova, L. Danihel, S. Polak, I. Varga, Ki67, PCNA, and MCM proteins: markers of proliferation in the diagnosis of breast cancer. Acta Histochem. 118(5), 544–552 (2016)PubMedCrossRef M. Jurikova, L. Danihel, S. Polak, I. Varga, Ki67, PCNA, and MCM proteins: markers of proliferation in the diagnosis of breast cancer. Acta Histochem. 118(5), 544–552 (2016)PubMedCrossRef
33.
Zurück zum Zitat C.Y. Loh, J.Y. Chai, T.F. Tang, W.F. Wong, G. Sethi, M.K. Shanmugam, P.P. Chong, C.Y. Looi, The E-Cadherin and N-Cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges. Cells 8(10), (2019). C.Y. Loh, J.Y. Chai, T.F. Tang, W.F. Wong, G. Sethi, M.K. Shanmugam, P.P. Chong, C.Y. Looi, The E-Cadherin and N-Cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges. Cells 8(10), (2019).
35.
Zurück zum Zitat M.I. Abdullah, S.M. Junit, K.L. Ng, J.J. Jayapalan, B. Karikalan, O.H. Hashim, Papillary thyroid cancer: genetic alterations and molecular biomarker investigations. Int. J. Med. Sci. 16(3), 450–460 (2019)PubMedPubMedCentralCrossRef M.I. Abdullah, S.M. Junit, K.L. Ng, J.J. Jayapalan, B. Karikalan, O.H. Hashim, Papillary thyroid cancer: genetic alterations and molecular biomarker investigations. Int. J. Med. Sci. 16(3), 450–460 (2019)PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat S. Ulisse, E. Baldini, A. Lauro, D. Pironi, D. Tripodi, E. Lori, I.C. Ferent, M.I. Amabile, A. Catania, F.M. Di Matteo, F. Forte, A. Santoro, P. Palumbo, V. D’Andrea, S. Sorrenti, Papillary thyroid cancer prognosis: an evolving field. Cancers (Basel) 13(21), (2021). S. Ulisse, E. Baldini, A. Lauro, D. Pironi, D. Tripodi, E. Lori, I.C. Ferent, M.I. Amabile, A. Catania, F.M. Di Matteo, F. Forte, A. Santoro, P. Palumbo, V. D’Andrea, S. Sorrenti, Papillary thyroid cancer prognosis: an evolving field. Cancers (Basel) 13(21), (2021).
37.
Zurück zum Zitat X. Kong, J. Zhang, J. Li, J. Shao, L. Fang, MiR-130a-3p inhibits migration and invasion by regulating RAB5B in human breast cancer stem cell-like cells. Biochem. Biophys. Res. Commun. 501(2), 486–493 (2018)PubMedCrossRef X. Kong, J. Zhang, J. Li, J. Shao, L. Fang, MiR-130a-3p inhibits migration and invasion by regulating RAB5B in human breast cancer stem cell-like cells. Biochem. Biophys. Res. Commun. 501(2), 486–493 (2018)PubMedCrossRef
38.
Zurück zum Zitat J. Zhu, Y. Luo, Y. Zhao, Y. Kong, H. Zheng, Y. Li, B. Gao, L. Ai, H. Huang, J. Huang, Z. Li, C. Chen, circEHBP1 promotes lymphangiogenesis and lymphatic metastasis of bladder cancer via miR-130a-3p/TGFbetaR1/VEGF-D signaling. Mol. Ther. 29(5), 1838–1852 (2021)PubMedPubMedCentralCrossRef J. Zhu, Y. Luo, Y. Zhao, Y. Kong, H. Zheng, Y. Li, B. Gao, L. Ai, H. Huang, J. Huang, Z. Li, C. Chen, circEHBP1 promotes lymphangiogenesis and lymphatic metastasis of bladder cancer via miR-130a-3p/TGFbetaR1/VEGF-D signaling. Mol. Ther. 29(5), 1838–1852 (2021)PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat B. Hu, H. Zhang, Z. Wang, F. Zhang, H. Wei, L. Li, LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4. Cancer Biol. Ther. 18(12), 974–983 (2017)PubMedPubMedCentralCrossRef B. Hu, H. Zhang, Z. Wang, F. Zhang, H. Wei, L. Li, LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4. Cancer Biol. Ther. 18(12), 974–983 (2017)PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat H. Wang, X. Huo, X.R. Yang, J. He, L. Cheng, N. Wang, X. Deng, H. Jin, N. Wang, C. Wang, F. Zhao, J. Fang, M. Yao, J. Fan, W. Qin, STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4. Mol. Cancer 16(1), 136 (2017)PubMedPubMedCentralCrossRef H. Wang, X. Huo, X.R. Yang, J. He, L. Cheng, N. Wang, X. Deng, H. Jin, N. Wang, C. Wang, F. Zhao, J. Fang, M. Yao, J. Fan, W. Qin, STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4. Mol. Cancer 16(1), 136 (2017)PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat Q. Fan, T. Huang, X. Sun, X. Yang, J. Wang, Y. Liu, T. Ni, S. Gu, Y. Li, Y. Wang, miR-130a-3p promotes cell proliferation and invasion by targeting estrogen receptor alpha and androgen receptor in cervical cancer. Exp. Ther. Med. 21(5), 414 (2021)PubMedPubMedCentralCrossRef Q. Fan, T. Huang, X. Sun, X. Yang, J. Wang, Y. Liu, T. Ni, S. Gu, Y. Li, Y. Wang, miR-130a-3p promotes cell proliferation and invasion by targeting estrogen receptor alpha and androgen receptor in cervical cancer. Exp. Ther. Med. 21(5), 414 (2021)PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat M. Wang, X. Wang, W. Liu, MicroRNA130a3p promotes the proliferation and inhibits the apoptosis of cervical cancer cells via negative regulation of RUNX3. Mol. Med. Rep. 22(4), 2990–3000 (2020)PubMed M. Wang, X. Wang, W. Liu, MicroRNA130a3p promotes the proliferation and inhibits the apoptosis of cervical cancer cells via negative regulation of RUNX3. Mol. Med. Rep. 22(4), 2990–3000 (2020)PubMed
43.
Zurück zum Zitat X. Dai, X. Guo, J. Liu, A. Cheng, X. Peng, L. Zha, Z. Wang, Circular RNA circGRAMD1B inhibits gastric cancer progression by sponging miR-130a-3p and regulating PTEN and p21 expression. Aging (Albany NY) 11(21), 9689–9708 (2019)PubMedCrossRef X. Dai, X. Guo, J. Liu, A. Cheng, X. Peng, L. Zha, Z. Wang, Circular RNA circGRAMD1B inhibits gastric cancer progression by sponging miR-130a-3p and regulating PTEN and p21 expression. Aging (Albany NY) 11(21), 9689–9708 (2019)PubMedCrossRef
44.
Zurück zum Zitat E.A. Toraih, R.M. Elshazli, L.N. Trinh, M.H. Hussein, A.A. Attia, E.M.L. Ruiz, M. Zerfaoui, M.S. Fawzy, E. Kandil, Diagnostic and prognostic performance of liquid biopsy-derived exosomal MicroRNAs in thyroid cancer patients: a systematic review and meta-analysis. Cancers (Basel) 13(17), (2021). E.A. Toraih, R.M. Elshazli, L.N. Trinh, M.H. Hussein, A.A. Attia, E.M.L. Ruiz, M. Zerfaoui, M.S. Fawzy, E. Kandil, Diagnostic and prognostic performance of liquid biopsy-derived exosomal MicroRNAs in thyroid cancer patients: a systematic review and meta-analysis. Cancers (Basel) 13(17), (2021).
45.
Zurück zum Zitat W. Song, C. Guo, J. Chen, S. Duan, Y. Hu, Y. Zou, H. Chi, J. Geng, J. Zhou, Silencing PSME3 induces colorectal cancer radiosensitivity by downregulating the expression of cyclin B1 and CKD1. Exp. Biol. Med. (Maywood) 244(16), 1409–1418 (2019)PubMedCrossRef W. Song, C. Guo, J. Chen, S. Duan, Y. Hu, Y. Zou, H. Chi, J. Geng, J. Zhou, Silencing PSME3 induces colorectal cancer radiosensitivity by downregulating the expression of cyclin B1 and CKD1. Exp. Biol. Med. (Maywood) 244(16), 1409–1418 (2019)PubMedCrossRef
46.
Zurück zum Zitat L. Yu, J.J. Li, X.L. Liang, H. Wu, Z. Liang, PSME3 promotes TGFB1 secretion by pancreatic cancer cells to induce pancreatic stellate cell proliferation. J. Cancer 10(9), 2128–2138 (2019)PubMedPubMedCentralCrossRef L. Yu, J.J. Li, X.L. Liang, H. Wu, Z. Liang, PSME3 promotes TGFB1 secretion by pancreatic cancer cells to induce pancreatic stellate cell proliferation. J. Cancer 10(9), 2128–2138 (2019)PubMedPubMedCentralCrossRef
47.
Zurück zum Zitat Z. Yi, D. Yang, X. Liao, F. Guo, Y. Wang, X. Wang, PSME3 induces epithelial-mesenchymal transition with inducing the expression of CSC markers and immunosuppression in breast cancer. Exp. Cell Res. 358(2), 87–93 (2017)PubMedCrossRef Z. Yi, D. Yang, X. Liao, F. Guo, Y. Wang, X. Wang, PSME3 induces epithelial-mesenchymal transition with inducing the expression of CSC markers and immunosuppression in breast cancer. Exp. Cell Res. 358(2), 87–93 (2017)PubMedCrossRef
48.
Zurück zum Zitat Z.C. Zhu, J.W. Liu, C. Yang, M.J. Li, R.J. Wu, Z.Q. Xiong, Targeting KPNB1 overcomes TRAIL resistance by regulating DR5, Mcl-1 and FLIP in glioblastoma cells. Cell Death Dis. 10(2), 118 (2019)PubMedPubMedCentralCrossRef Z.C. Zhu, J.W. Liu, C. Yang, M.J. Li, R.J. Wu, Z.Q. Xiong, Targeting KPNB1 overcomes TRAIL resistance by regulating DR5, Mcl-1 and FLIP in glioblastoma cells. Cell Death Dis. 10(2), 118 (2019)PubMedPubMedCentralCrossRef
Metadaten
Titel
MicroRNA-130a-3p impedes the progression of papillary thyroid carcinoma through downregulation of KPNB1 by targeting PSME3
verfasst von
Yan Wang
Jinmei Xu
Xiaodan Zhu
Hongyu Kuang
Publikationsdatum
11.05.2023
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 1/2023
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-023-03383-x

Weitere Artikel der Ausgabe 1/2023

Endocrine 1/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.